Brad Canino
Stock Analyst at Guggenheim
(4.56)
# 246
Out of 5,112 analysts
23
Total ratings
63.16%
Success rate
31.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brad Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GLTO Galecto | Maintains: Buy | $32 → $36 | $26.00 | +38.46% | 2 | Dec 8, 2025 | |
| BDTX Black Diamond Therapeutics | Downgrades: Neutral | n/a | $2.54 | - | 2 | Dec 4, 2025 | |
| NUVL Nuvalent | Maintains: Buy | $125 → $155 | $101.34 | +52.95% | 2 | Nov 18, 2025 | |
| PYXS Pyxis Oncology | Maintains: Buy | $5 → $7 | $1.73 | +304.62% | 2 | Nov 4, 2025 | |
| KYMR Kymera Therapeutics | Assumes: Buy | $90 | $79.63 | +13.02% | 1 | Nov 3, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Buy | $40 | $17.04 | +134.74% | 2 | Oct 22, 2025 | |
| CGON CG Oncology | Initiates: Buy | $90 | $38.00 | +136.84% | 1 | Oct 8, 2025 | |
| OLMA Olema Pharmaceuticals | Initiates: Buy | $20 | $30.81 | -35.09% | 1 | Oct 8, 2025 | |
| CELC Celcuity | Initiates: Buy | $110 | $99.16 | +10.93% | 1 | Sep 22, 2025 | |
| ORIC ORIC Pharmaceuticals | Assumes: Buy | $18 | $8.09 | +122.63% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $15 | $8.13 | +84.50% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.01 | +298.01% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $72 | $14.04 | +412.82% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $9.85 | - | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $450 | $29.10 | +1,446.39% | 1 | Mar 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $26.40 | +108.33% | 1 | Mar 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $42.57 | -29.53% | 2 | Mar 31, 2021 |
Galecto
Dec 8, 2025
Maintains: Buy
Price Target: $32 → $36
Current: $26.00
Upside: +38.46%
Black Diamond Therapeutics
Dec 4, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.54
Upside: -
Nuvalent
Nov 18, 2025
Maintains: Buy
Price Target: $125 → $155
Current: $101.34
Upside: +52.95%
Pyxis Oncology
Nov 4, 2025
Maintains: Buy
Price Target: $5 → $7
Current: $1.73
Upside: +304.62%
Kymera Therapeutics
Nov 3, 2025
Assumes: Buy
Price Target: $90
Current: $79.63
Upside: +13.02%
Summit Therapeutics
Oct 22, 2025
Reiterates: Buy
Price Target: $40
Current: $17.04
Upside: +134.74%
CG Oncology
Oct 8, 2025
Initiates: Buy
Price Target: $90
Current: $38.00
Upside: +136.84%
Olema Pharmaceuticals
Oct 8, 2025
Initiates: Buy
Price Target: $20
Current: $30.81
Upside: -35.09%
Celcuity
Sep 22, 2025
Initiates: Buy
Price Target: $110
Current: $99.16
Upside: +10.93%
ORIC Pharmaceuticals
Sep 4, 2025
Assumes: Buy
Price Target: $18
Current: $8.09
Upside: +122.63%
Sep 4, 2025
Assumes: Buy
Price Target: $15
Current: $8.13
Upside: +84.50%
Sep 4, 2025
Initiates: Buy
Price Target: $8
Current: $2.01
Upside: +298.01%
Sep 4, 2025
Initiates: Buy
Price Target: $72
Current: $14.04
Upside: +412.82%
Sep 4, 2025
Initiates: Neutral
Price Target: n/a
Current: $9.85
Upside: -
Mar 31, 2021
Initiates: Neutral
Price Target: $450
Current: $29.10
Upside: +1,446.39%
Mar 31, 2021
Initiates: Outperform
Price Target: $55
Current: $26.40
Upside: +108.33%
Mar 31, 2021
Initiates: Outperform
Price Target: $30
Current: $42.57
Upside: -29.53%